Go to Top
(312) 815-8986tract@tracttherapeutics.com
    TRACT Therapeutics, Inc.
    • Home
    • About
      • Management & Advisors
    • Technology Overview
      • Autoimmune Disease
      • Organ Transplantation
    • Clinical Pipeline
    • Patients
    • Investors
    • News
    • Contact
    • Home
    • About
    • Management & Advisors
    • Technology Overview
    • Organ Transplantation
    • Clinical Pipeline
    • Patients
    • Investors
    • News & Events
    • Contact

    Results of a Phase 1 Trial of Treg Adoptive Cell Transfer (TRACT) in De Novo Living Donor Kidney Transplant Recipients

    • TRACT Therapeutics, Inc./
    • Blog/
    • Results of a Phase 1 Trial of Treg Adoptive Cell Transfer (TRACT) in De Novo Living Donor Kidney Transplant Recipients
    • TRACT Therapeutics, Inc. Launches the TRACT CryoBanking Program™ to Collect and Bank a Patient’s Immune Cells for Future Treatment
    • SCIENTIFIC REPORTS, A Phase I Clinical Trial with Ex Vivo Expanded Recipient Regulatory T Cells in Living Donor Kidney Transplants” April 2018.
    Jun 25 2016

    Results of a Phase 1 Trial of Treg Adoptive Cell Transfer (TRACT) in De Novo Living Donor Kidney Transplant Recipients

    Download Full Presentation

    Posted in: Uncategorized
      • Resources:
      • Mayne, C.G., Williams, C.B., Induced and natural regulatory T cells in the development of inflammatory bowel disease. Inflamm Bowel Dis, 2013. 19(8): p. 1772-88. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3690174/
      • Himmel, M.E., et al., Regulatory T-cell therapy for inflammatory bowel disease: more questions than answers. Immunology, 2012. 136(2): p. 115-22. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3403270/
    © TRACT Therapeutics, Inc. 2015